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Abstract
Introduction: Erythema nodosum is often associated with a distressing symptomatology, including painful
subcutaneous nodules, polyarthropathy, and significant fatigue. Whilst it is a well-documented side-effect of
estrogen therapy in females, we describe what we believe to be the first report in the literature of erythema
nodosum as a result of estrogen therapy in a male.
Case presentation: A 64-year-old Afro-Caribbean man with locally advanced carcinoma of the prostate agreed
to participate in a randomized controlled trial comparing estrogen patches with luteinizing hormone-releasing
hormone analogs to achieve androgen deprivation, and was allocated to the group receiving estrogen patches.
One month later he presented with tender lesions on his shins and painful swelling of his ankles, wrists, and
left shoulder. This was followed by progressive severe fatigue that required hospital admission, where he was
diagnosed with erythema nodosum by a rheumatologist. Two months after discontinuing the estrogen patches
the erythema nodosum, and associated symptoms, had fully resolved, and to date he remains well with no further
recurrence.
Conclusion: Trial results may establish transdermal estrogen as an alternative to luteinizing hormone-releasing
hormone analogs in the management of prostate cancer, and has already been established as a therapy for male to
female transsexuals. It is essential to record the toxicity profile of transdermal estrogen in men to ensure accurate
safety information. This case report highlights a previously undocumented toxicity of estrogen therapy in men, of
which oncologists, urologists, and endocrinologists need to be aware. Rheumatologists and dermatologists should
add estrogen therapy to their differential diagnosis of men presenting with erythema nodosum.
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Introduction
Erythema nodosum classically presents as raised tender
nodules in the skin and subcutaneous tissue. These nod-
ules are most commonly distributed on the lower ex-
tremities, particularly the pretibial surfaces, but may
occur in other anatomical locations including the thighs
and extensor aspects of the forearms. Other associated
symptoms may include fever, arthralgia, and generalized
weakness [1]. Whilst it is thought to represent a hyper-
sensitivity reaction, determining the etiology of erythema
nodosum is notoriously difficult, with the resulting
uncertainty causing patients additional distress. The under-
lying causes include infections, (most commonly Group A
streptococcus, but also hepatitis B and C, human immu-
nodeficiency virus, tuberculosis, and mycoplasma pneu-
monia), disease processes (including inflammatory bowel
disease, sarcoidosis, and Behçet’s disease), elevated hormo-
nal states (pregnancy), malignancy (for example, Hodgkin’s
lymphoma), and medications (estrogens, sulfonamides,
penicillins), and up to 55 % of cases are thought to be idio-
pathic in origin [2].
Erythema nodosum most commonly occurs in young
women. A recent Italian case series (n = 124) found that
the ratio of females to males was 10:1 and the mean age
of onset was 39.5 years old [3]. The propensity towards
females is at least partially due to estrogen exposure; in
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this series, 6.5 % of cases occurred during pregnancy
and 5.6 % were attributed to a combination of estrogen-
based and progesterone-based medications [3].
The toxicity profile of estrogen is established mainly
from its use in women. Toxicities specific to females
include breast pain, endometrial hyperplasia, and an
increased risk of breast and endometrial cancer [4]. Ad-
verse effects unrelated to gender include venous and arter-
ial thromboembolism, cardiovascular morbidity including
cerebrovascular accident, and myocardial infarction [4].
The consequences of estrogen therapy in males may be
attributed to either the resulting low testosterone levels
(loss of libido, impotence, and hot flushes) or to the direct
effects of estrogen (gynecomastia).
Most established indications for estrogen therapy are
in women, for example, as a treatment for the symptoms
and sequelae of estrogen deficiency in post-menopausal
women, and in combination with progesterone as a con-
traceptive. In males, estrogen therapy is currently used
in the treatment of male to female transsexuals [5],
and transdermal estrogen is currently being investigated
as a potential therapy for men with prostate cancer.
Androgen deprivation therapy resulting in testosterone
suppression is a key strategy in the management of pros-
tate cancer. This is mainly achieved through the use of
luteinizing hormone-releasing hormone (LHRH) analogs,
and occasionally by surgical orchidectomy. Historically,
oral estrogen (diethylstilboestrol) has been used for andro-
gen deprivation therapy; however, it is not used routinely
because of cardiovascular toxicity attributed to first-pass
hepatic metabolism [6]. Transdermal administration of
estrogen avoids the entero-hepatic circulation and so is
expected to mitigate the risk of cardiovascular toxicity [7].
PATCH (Prostate Adenocarcinoma: TransCutaneous
Hormones Trial) is a randomized controlled trial of trans-
cutaneous estrogen patches versus LHRH analogs. An
early analysis of toxicity in PATCH (n = 138) revealed that
men allocated estrogen patches experienced gynecomastia
(75 %), impotence (57 %), loss of libido (56 %), and hot
flushes (25 %) within the first 6 months of using the
patches, though most effects were mild (mainly Common
Terminology Criteria for Adverse Events [CTCAE] grade
1 or 2) [8]. In addition to these effects, the consequences
of estrogen therapy in male to female transsexuals include
redistribution of body fat, decreased muscle mass and
strength, softening of skin, and decreased terminal hair
growth [5]. To date, there have been no reports in the
literature of erythema nodosum developing as a result of
estrogen therapy in a man.
Case presentation
A 64-year-old Afro-Caribbean man with locally advanced
adenocarcinoma of the prostate (T4 NO MO, Gleason
score 4+5) was randomized to the transdermal estrogen
arm (initially, three Merck Estrogen Femseven patches
100 μg/24 hours, changed twice a week) of the PATCH
study (control arm was an LHRH analog). Four weeks
later he developed tender lesions on his shins (Fig. 1) asso-
ciated with painful swelling in his ankles, wrists, and left
shoulder, which was followed by progressive severe fa-
tigue. On review by an oncologist, there were initial con-
cerns that the combination of swollen ankles and fatigue
could be a result of heart failure secondary to estrogen-
induced cardiovascular toxicity. His testosterone level had
also fallen to castrate levels, and the number of estrogen
patches administered was changed to twice weekly as
mandated in the trial protocol. He was then seen by his
general practitioner and on examination was found to
have bilateral subconjunctival hematomas in addition to
the tender nodules on his shins. He was treated with oral
diclofenac and misoprostol, oral cephalexin, and chloram-
phenicol eye drops. His symptoms persisted despite these
interventions and 1 week later the decision was made to
discontinue the estrogen patches and switch his therapy
to an LHRH analog (goserelin).
Two weeks after switching to the LHRH analog, he
was admitted to hospital with worsening fatigue and
Fig. 1 A photograph of bilateral shin lesions taken at the time of
first presentation
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arthralgia. He was found to have sinus tachycardia (115
beats per minute) with no other abnormalities on
electrocardiogram, elevated C-reactive protein (122 mg/L,
normal <8 mg/L), and elevated alkaline phosphatase
(265 u/L, normal range 30–130 u/L). He had recently
had a chest X-ray with no abnormal findings, and tested
negative for tuberculosis. Streptococcal infection was also
excluded.
Our patient was reviewed by a rheumatologist, who
confirmed a diagnosis of erythema nodosum as a result
of estrogen therapy. His symptoms resolved 8 weeks
after discontinuing the estrogen patches (replaced with
the LHRH analog), and to date he remains well with no
further recurrence. A serious adverse event form was
completed describing grade 2 arthralgia and grade 2 per-
ipheral edema (CTCAE v3.0). As a serious and unexpec-
ted toxicity of estrogen patches in men, this was reported
to the Medicines and Healthcare products Regulatory
Agency as a “suspected unexpected serious adverse
reaction.”
Discussion
Attributing the underlying etiology of erythema nodosum
relies on the exclusion of other potential causes that fit
with the case history. Behçet’s disease may also present
with a combination of erythema nodosum and ophthalmic
signs, however Behçet’s disease is usually associated with
redness and inflammation of the eyes rather than bilateral
subconjunctival hematomas, and the absence of any of
other features (recurrent mouth and genital ulcers) made
this an unlikely diagnosis. Another etiology considered
was infection, given the finding of raised C-reactive pro-
tein; however, no infective source was identified. Whilst
an infectious etiology could not be excluded, given that
the initiation and discontinuation of estrogen patches cor-
responded with the emergence and resolution of erythema
nodosum, it seemed highly probable that estrogen was the
underlying cause in this case.
Conclusions
This case report highlights a rare toxicity of estrogen
therapy, with only one case recorded, at the time of sub-
mission, in 448 patients receiving transdermal estrogen
in PATCH with an estimated total of 1120 patient-years
of exposure, and no other cases reported in the literature
to the best of our knowledge. Transdermal estrogen is
already prescribed for male to female transsexuals, and,
depending on the findings of PATCH, may be used as an
alternative to LHRH analogs in the management of pros-
tate cancer. Transdermal estrogen should be added to the
differential diagnosis of men with erythema nodosum, and
all health professionals prescribing transdermal estrogen
need to be aware of this potential toxicity.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Abbreviations
CTCAE v3.0: Common Terminology Criteria for Adverse Events Version 3.0;
LHRH: luteinizing hormone-releasing hormone; PATCH: Prostate
Adenocarcinoma: TransCutaneous Hormones trial.
Competing interests
RL and PA are Co-Principal Investigators of PATCH. The authors declare that
they have no competing interests.
Authors’ contributions
RL and PA conceived the manuscript. CC performed a literature search and
wrote the manuscript. SM acquired patient information. SM, PA, and RL
revised the manuscript critically for important intellectual content and all
authors reviewed and approved the final version of the manuscript.
Acknowledgements
PATCH is supported by the Medical Research Council Clinical Trials Unit at
University College London funded by Cancer Research UK.
Author details
1MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London
WC2B 6NH, UK. 2Imperial College Healthcare NHS Trust, Charing Cross
Hospital, Fulham Palace Road, London W6 8RF, UK. 3Department of Surgery,
‘B’ Block Hammersmith Campus, Imperial College Faculty of Medicine,
DuCane Road, London W12 0NN, UK. 4Department of Urology (3N), Charing
Cross Hospital, Imperial College Healthcare NHS Trust, Fulham Palace Road,
London W6 8RF, UK.
Received: 10 April 2015 Accepted: 25 November 2015
References
1. Cribier B, Caille A, Heid E, Grosshans E. Erythema nodosum and associated
diseases. A study of 129 cases. Int J Dermatol. 1998;37(9):667–72.
2. Blake T, Manahan M, Rodins K. Erythema nodosum - a review of an
uncommon panniculitis. Dermatol Online J. 2014;20(4):22376.
3. Papagrigoraki A, Gisondi P, Rosina P, Cannone M, Girolomoni G. Erythema
nodosum: etiological factors and relapses in a retrospective cohort study.
Eur J Dermatol. 2010;20(6):773–7. doi:10.1684/ejd.2010.1116.
4. MHRA. Summary of Product Characteristics (SmPC) FemSeven® 100,
100 micrograms/24 hours, transdermal patch. http://www.mhra.gov.uk/
home/groups/spcpil/documents/spcpil/con1437714884499.pdf Accessed 19
Mar 2015.
5. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, Gooren LJ,
Meyer III WJ, Spack NP, et al. Endocrine treatment of transsexual persons:
an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab.
2009;94(9):3132–54. doi:10.1210/jc.2009-0345.
6. Phillips I, Shah SI, Duong T, Abel P, Langley RE. Androgen deprivation
therapy and the re-emergence of parenteral estrogen in prostate cancer.
Oncol Hematol Rev. 2014;10(1):42–7.
7. Ockrim JL, el Lalani N, Kakkar AK, Abel PD. Transdermal estradiol therapy
for prostate cancer reduces thrombophilic activation and protects against
thromboembolism. J Urol. 2005;174(2):527–33. discussion 32–3.
8. Langley RE, Cafferty FH, Alhasso AA, Rosen SD, Sundaram SK, Freeman SC,
et al. Cardiovascular outcomes in patients with locally advanced and
metastatic prostate cancer treated with luteinising-hormone-releasing-
hormone agonists or transdermal estrogen: the randomised, phase 2
MRC PATCH trial (PR09). Lancet Oncol. 2013;14(4):306–16.
doi:10.1016/S1470-2045(13)70025-1.
Coyle et al. Journal of Medical Case Reports  (2015) 9:285 Page 3 of 3
